$2.21
0.91% yesterday
Nasdaq, Sep 03, 10:08 pm CET
ISIN
US4622601007
Symbol
IOVA

Iovance Biotherapeutics Inc Stock price

$2.21
-0.62 21.91% 1M
-1.83 45.30% 6M
-5.19 70.14% YTD
-8.64 79.63% 1Y
-8.77 79.87% 3Y
-29.12 92.95% 5Y
-4.66 67.83% 10Y
-3.00 57.57% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.02 0.91%
ISIN
US4622601007
Symbol
IOVA
Industry

Key metrics

Basic
Market capitalization
$799.7m
Enterprise Value
$499.5m
Net debt
positive
Cash
$301.2m
Shares outstanding
341.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.3 | 2.9
EV/Sales
2.1 | 1.8
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
78.0%
Return on Equity
-52.4%
ROCE
-52.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$241.5m | $274.7m
EBITDA
$-360.1m | $-358.4m
EBIT
$-410.6m | $-384.6m
Net Income
$-389.9m | $-389.0m
Free Cash Flow
$-323.5m
Growth (TTM | estimate)
Revenue
637.1% | 67.4%
EBITDA
16.1% | -4.1%
EBIT
10.6% | 0.9%
Net Income
11.4% | -4.5%
Free Cash Flow
19.2%
Margin (TTM | estimate)
Gross
20.6%
EBITDA
-149.1% | -130.5%
EBIT
-170.0%
Net
-161.4% | -141.6%
Free Cash Flow
-134.0%
More
EPS
$-1.2
FCF per Share
$-0.9
Short interest
21.4%
Employees
838
Rev per Employee
$200.0k
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Iovance Biotherapeutics Inc forecast:

12x Buy
67%
5x Hold
28%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
67%
Hold
28%
Sell
6%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
242 242
637% 637%
100%
- Direct Costs 192 192
305% 305%
79%
50 50
442% 442%
21%
- Selling and Administrative Expenses 161 161
26% 26%
67%
- Research and Development Expense 292 292
8% 8%
121%
-360 -360
16% 16%
-149%
- Depreciation and Amortization 51 51
69% 69%
21%
EBIT (Operating Income) EBIT -411 -411
11% 11%
-170%
Net Profit -390 -390
11% 11%
-161%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:
Neutral
The Motley Fool
8 days ago
For a roller-coaster stock, look no further than Iovance Biotherapeutics (IOVA -1.22%).
Neutral
The Motley Fool
9 days ago
Monday won't go down as a particularly memorable trading session on the stock market. It also won't be marked as a great day for shareholders of biotech Iovance Biotherapeutics (IOVA -5.95%).
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 838
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today